Results 41 to 50 of about 20,430,225 (174)

Differentiation of clear cell and non clear cell renal cell carcinoma through high-frame-rate contrast-enhanced ultrasound

Scientific Reports
Objective To evaluate the value of high-frame-rate contrast-enhanced ultrasound (H-CEUS) in differentiating between clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC).
Wenxin Yuan, Jingling Wang, Hailan Wu, Long Gao, Zhixing Liu, Weiping Zhang   +5 more
doaj   +1 more source

Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches

International Journal of Translational Medicine, 2022
Non-clear cell renal cell carcinomas (nccRCC) are a diverse group of kidney cancers with histopathologically and genetically heterogeneous features. About 25% of renal cell carcinomas (RCCs) are nccRCC types.
Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, Anastasia Shpichka, Peter Timashev, Nikoo Hossein-Khannazer, Massoud Vosough   +6 more
doaj   +1 more source

Long Range Development Plan: The University of Houston at Clear Lake City [PDF]

, 2016
28cm x 28cmThis publication, prepared by the Office of Facilities Planning and Operations, presents goals, plans, and concepts of the new Clear Lake ...
Office of Facilities Planning and Operations, University of Houston at Clear Lake City
core   +1 more source

Targeted Therapy for Metastatic Renal Cell Carcinoma

Acta Medica Indonesiana, 2017
In the past 10 years, recent development of targeted therapy in metastatic renal cell carcinoma (mRCC) has provided a new hope and significantly enhanced the prognosis of the disease.
Andika Afriansyah, Agus Rizal AH. Hamid, Chaidir A Mochtar, Rainy Umbas   +3 more
doaj   +2 more sources

Booklet for the dedication of the Clear Lake Graduate Center [PDF]

, 2017
This booklet contains the program for and credits of those involved with the Clear Lake Graduate Center, dedicated on Thursday, May 4 ...

core   +1 more source

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma [PDF]

Asia-Pacific Journal of Clinical Oncology, 2015
This study evaluated the safety and efficacy of sunitinib in the treatment of advanced non-clear cell renal cell carcinoma.Thirty-seven Chinese patients with advanced non-clear cell renal cell carcinoma were enrolled from October 2008 to October 2013. Sunitinib monotherapy was administered in repeated 6-week cycles of daily oral administration of 50 mg
Hong-Zhe, Shi, Jun, Tian, Chang-Ling, Li
openaire   +2 more sources

Genomic profiles of renal cell carcinoma in a small Chinese cohort

Frontiers in Oncology, 2023
ObjectivesOur aim was to describe the molecular characteristics of Renal Cell Carcinoma (RCC) and develop a small panel of RCC-associated genes from a large panel of cancer-related genes.Materials and methodsClinical data of 55 patients with RCC ...
Sheng Tai, Sheng Tai, Sheng Tai, Dan-dan Xu, Dan-dan Xu, Zhixian Yu, Yu Guan, Yu Guan, Shuiping Yin, Shuiping Yin, Shuiping Yin, Jun Xiao, Song Xue, Chaozhao Liang, Chaozhao Liang, Chaozhao Liang   +15 more
doaj   +1 more source

DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma

BMC Cancer, 2019
Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer and is associated with poor prognosis if metastasized. Up to one third of patients with local disease at diagnosis will develop metastasis after nephrectomy,
Emma Andersson Evelönn, Mattias Landfors, Zahra Haider, Linda Köhn, Börje Ljungberg, Göran Roos, Sofie Degerman   +6 more
doaj   +1 more source

Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease

Frontiers in Oncology, 2022
Collecting duct renal cell carcinoma (cdRCC), which until recently was thought to arise from the collecting ducts of Bellini in the renal medulla, is a rare and aggressive type of non-clear renal cell carcinoma (ncRCC), accounting for 1% of all renal ...
Cristina Suarez, David Marmolejo, Augusto Valdivia, Rafael Morales-Barrera, Macarena Gonzalez, Joaquin Mateo, Maria Eugenia Semidey, David Lorente, Enrique Trilla, Joan Carles   +9 more
doaj   +1 more source

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma [PDF]

, 2021
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response.
Schnidrig, D, Sunderland, MW, Ghorani, E, Lingard, K, Rowan, A, Jamal-Hanjani, M, Litchfield, K, Turajlic, S, Becker, PD, Swanton, C, Borg, E, PEACE Consortium, Hatipoglu, E, Mahadeva, U, Xu, H, Hazell, S, Mitchison, M, Green, A, TRACERx Renal Consortium, Reading, JL, Sarker, S, Robert de Massy, M, Nicol, D, TRACERx Renal Consortium,, Falzon, M, López, JI, Edmonds, K, Carlyle, E, Mason, R, Salgado, R, Vasquez, MD, Uddin, I, Au, L, Proctor, I, Yang, WW, Quezada, SA, Spencer, C, Fotiadis, N, Shepherd, STC, Mangwende, M, Dhillon, K, Joshi, K, Lund, T, Byrne, F, Horswell, S, Beattie, G, Moore, DA, PEACE Consortium,, Furness, AJS, Puccio, I, Akarca, A, Thompson, R, Larkin, J, Chain, B, Del Rosario, L, Fendler, A, Pickering, L, Kassiotis, G, Marafioti, T, Attig, J   +59 more
core   +1 more source